User-centred design for machine learning in health care: a case study from care management.

Objectives: Few machine learning (ML) models are successfully deployed in clinical practice. One of the common pitfalls across the field is inappropriate problem formulation: designing ML to fit the data rather than to address a real-world clinical pain point.

Methods: We introduce a practical toolkit for user-centred design consisting of four questions covering: (1) solvable pain points, (2) the unique value of ML (eg, automation and augmentation), (3) the actionability pathway and (4) the model's reward function.

Acquired Cold-Induced Urticaria in Pediatric Patients: A 22-Year Experience in a Tertiary Care Center (1996-2017).

Background: Acquired cold-induced urticaria (ACU) has not been well evaluated in pediatrics.

Objective: To further evaluate the presentation of ACU in children and associated risk of anaphylaxis.

Methods: A retrospective chart review was performed in children 18 years or younger diagnosed with ACU at Boston Children's Hospital (US, Northeast) from 1996 to 2017.

Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab.

Background: We successfully used omalizumab to facilitate peanut oral immunotherapy (OIT) in children with reactivity to ≤50mg peanut protein and with high peanut IgE (median, 229 kU/L).

Objective: We report on long-term OIT outcomes in these patients, including dosing changes, adverse events, peanut immunoglobulin changes, and quality of life (QoL).

Methods: Patients were followed for up to 72 months (67 months of maintenance).

A twenty-two-year experience with Hymenoptera venom immunotherapy in a US pediatric tertiary care center 1996-2018.

Background: The rate of systemic reactions (SRs) to venom immunotherapy (VIT) in children has not been well evaluated.

Objective: To evaluate the rate of SRs to VIT in pediatric patients age 5 to 18 years who were treated with a standard protocol.

Methods: A retrospective chart review was conducted to identify patients who received VIT at Boston Children's Hospital from 1996 through 2018.

Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy with and without Seasonal Dose Adjustment.

Background: The 2003 Joint Task Force on Practice Parameters recommended standardizing allergen subcutaneous immunotherapy (SCIT). Data from longitudinal surveillance survey in North America reported a systemic reaction (SR) rate of 0.1% to 0.